Q-omics provides the consensus-scored CRHBP profile across patient tissues and cancer cell-line models. CRHBP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CRHBP is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, CRHBP RNA expression shows 19,734 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where CRHBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRHBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRHBP survival associations across molecular data types. CRHBP RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRHBP RNA expression–survival associations across cancer types. High CRHBP expression shows unfavorable associations in UVM and BLCA, but favorable associations in KIRC, LIHC, PAAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CRHBP RNA expression.
This table summarizes CRHBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CRHBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRHBP shows lower tumor expression in KIRC, KIRP, KICH, COAD, LIHC and THCA. The KIRC box plot shows higher CRHBP RNA expression in normal versus tumor tissue (log2 FC = −4.138, t-test p < 0.001).
This table shows molecular features associated with CRHBP in patient tissues and cancer cell lines. In patient samples, CRHBP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CRHBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
